Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis.

[1]  Wei Chen,et al.  MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4 , 2013, British Journal of Cancer.

[2]  M. Lindsey,et al.  Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. , 2013, Pharmacology & therapeutics.

[3]  Linlin Tang,et al.  The urokinase plasminogen activator system in breast cancer invasion and metastasis. , 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  M. Langenskiöld,et al.  Differential Prognostic Impact of uPA and PAI-1 in Colon and Rectal Cancer , 2009, Tumor Biology.

[5]  M. Langenskiöld,et al.  uPA and PAI-1 in rectal cancer--relationship to radiotherapy and clinical outcome. , 2009, The Journal of surgical research.

[6]  P. Andreasen.  PAI-1 - a potential therapeutic target in cancer. , 2007, Current drug targets.

[7]  B. Aggarwal,et al.  Inflammation and cancer: how hot is the link? , 2006, Biochemical pharmacology.

[8]  M. Błaszczyńska,et al.  PROSTAGLANDINS AND CANCER , 2005, Gut.

[9]  Ketan Sheth1,et al.  Management of Hepatic Metastases from Colorectal Cancer , 2005, Clinics in colon and rectal surgery.

[10]  Hiroshi Sato,et al.  Roles of membrane‐type matrix metalloproteinase‐1 in tumor invasion and metastasis , 2005, Cancer science.

[11]  W. Fay.  Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. , 2004, Trends in cardiovascular medicine.

[12]  F. Schramel,et al.  Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  D. Lawrence,et al.  Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. , 2003, Current pharmaceutical design.

[14]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[15]  V. Kähäri,et al.  Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets , 2002, International journal of cancer.

[16]  P. Boyle,et al.  ABC of colorectal cancer: Epidemiology , 2000, BMJ.

[17]  Tatsuo Tanaka,et al.  Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size , 1999, Cancer.

[18]  G I Murray,et al.  Matrix metalloproteinases in tumour invasion and metastasis , 1999, The Journal of pathology.

[19]  K. Almholt,et al.  Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. , 1998, Current opinion in cell biology.

[20]  M. Skobe,et al.  Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.

[21]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1997 .

[22]  J. Guillem,et al.  Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Steingrimur Stefansson,et al.  The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin , 1996, Nature.

[24]  Michael V. Doyle,et al.  Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.

[25]  D. Loskutoff,et al.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? , 1996, The Journal of cell biology.

[26]  K. Preissner,et al.  The urokinase receptor is a major vitronectin-binding protein on endothelial cells. , 1996, Experimental cell research.

[27]  P. Quax,et al.  Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. , 1994, Gastroenterology.

[28]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.

[29]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[30]  廣畑 富雄,et al.  Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective , 2007 .

[31]  I. Talbot,et al.  Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. , 1996, Cancer research.

[32]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[33]  J. Verheijen,et al.  The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. , 1985, Scandinavian journal of clinical and laboratory investigation.